English | 简体中文 | 繁體中文 | 한국어
 All Press Releases

HashKey港股招股:乘行业东风而上 数字资产龙头成长潜力充足
Dec 10, 2025 18:52 HKT
HashKey港股招股:乘行業東風而上 數字資產龍頭成長潛力充足
Dec 10, 2025 18:12 HKT
MHI Successfully Produces Hydrogen at Its Ammonia Cracking Pilot Plant Using Steam Heating
Dec 10, 2025 17:14 HKT
'M' Mark Event - HKGX 2025 IBF World Championships
Dec 10, 2025 15:58 HKT
Techmer PM加入Formerra北美产品组合
Dec 10, 2025 15:34 HKT
HKiNEDA Annual Conference Successfully Concludes
Dec 10, 2025 15:11 HKT
香港獨立非執行董事協會週年會議圓滿舉行
Dec 10, 2025 15:11 HKT
Redefining Global Legal Services with Digital Intelligence China Entercom Empowers Yingke Law Firm to Win 2025 IDC China Future Enterprise Awards
Dec 10, 2025 14:37 HKT
智跨法域 數鏈全球 中企通信賦能盈科律師事務所榮膺2025 IDC中國未來企業獎項
Dec 10, 2025 14:37 HKT
智跨法域 数链全球 中企通信赋能盈科律师事务所荣膺2025 IDC中国未来企业奖项
Dec 10, 2025 14:37 HKT
Trio AI Partners with AbbyPay, a Member of PCG, to Pioneer the Future of AI-Powered Payments
Dec 10, 2025 12:12 HKT
三菱重工、蒸気加熱方式によるアンモニア分解パイロットプラントにて水素製造に成功
Dec 10, 2025 11:35 HKT
Trio AI與交易寶旗下成員AbbyPay攜手合作 開創AI賦能支付新未來
Dec 10, 2025 11:10 HKT
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Dec 10, 2025 11:00 HKT
Techmer PM加入Formerra北美產品組合
Dec 09, 2025 22:00 HKT
Majority of Australian Parents (65%) and U.S. Parents 58% Support Social Media Ban for Under 16s, but Kids Say It Risks Cutting Them Off from Key Connections
Dec 09, 2025 22:00 HKT
Techmer PM Joins Formerra's Portfolio in North America
Dec 09, 2025 22:00 HKT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 09, 2025 17:51 HKT
NEC Wins TIP MUST Silver Badge with Advanced Network Operating System for Open Optical Transponders
Dec 09, 2025 12:39 HKT
香港交易所科技100指數推出 易方達基金獲授權
Dec 09, 2025 12:26 HKT
<< Previous Next >>
 Releases By Language
All
English
Indonesian
Japanese
Korean
Thai
Trad. Chinese
Simp. Chinese
Vietnamese
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: